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Background: Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental
disorders of children and adolescents, with a significant impact on health services and the community in terms of
economic and social burdens. The objective of this systematic review will be to evaluate the comparative efficacy
and safety of pharmacological and non-pharmacological treatments in children and adolescents with ADHD.
Methods: Searches involving PubMed/MEDLINE and the Cochrane Database of Systematic Reviews will be used to
identify related systematic reviews and relevant randomized trials. Search results will be supplemented by reports
from the regulatory and health technology agencies, clinical trials registers and by data requested from trialists
and/or pharmaceutical companies. We will consider studies evaluating pharmacological interventions (e.g. stimulants,
non-stimulants, antidepressants), psychological interventions (e.g. behavioural interventions, cognitive training and
neurofeedback) and complementary and alternative medicine interventions (e.g. dietary interventions, supplement
with fatty acids, vitamins, minerals, aminoacids, herbal treatment, homeopathy, and mind-body interventions including
massage, chiropractic, acupuncture, yoga, meditation, Tai chi). Eligible control conditions will be placebo, waitlist, no
treatment and usual care. Randomized controlled trials of a minimum of 3 weeks duration will be included. The primary
outcomes of interest will be the proportion of patients who responded to treatment and who dropped out of the
allocated treatment, respectively. Secondary outcomes will include treatment discontinuation due to adverse events, as
well as the occurrences of serious adverse events and specific adverse events (decreased weight, anorexia, insomnia and
sleep disturbances, anxiety, syncope and cardiovascular events). Two reviewers will independently screen references
identified by the literature search, as well as potentially relevant full-text articles in duplicate. Data will be abstracted and
risk of bias will be appraised by two team members independently. Conflicts at all levels of screening and abstraction will
be resolved through discussion. Random-effects pairwise meta-analyses and Bayesian network meta-analyses will be
conducted where appropriate.
Discussion: This systematic review and network meta-analysis will compare the efficacy and safety of treatments used
for ADHD in children and adolescents. The findings will assist patients, clinicians and healthcare providers to make
evidence-based decisions regarding treatment selection.
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Attention deficit hyperactivity disorder (ADHD) is con-
sidered a chronic condition starting in childhood that is
comprised of a persistent pattern of symptoms of hyper-
activity, impulsiveness and/or lack of attention, which is
more frequent and severe than usual for that child’s age,
and causing a significant functional impairment in
school or work performance and in the activities of daily
life [1-5]. ADHD is one of the most common neurodeve-
lopmental disorders of children and adolescents [3,5],
with a considerable impact on health services and the
community in terms of economic and social burdens
[6-9]. The recent Global Burden of Disease Study (GBD
2010) revealed worldwide estimates of 26 million chil-
dren and adolescents with ADHD, representing 491,500
disability-adjusted life years (DALYs) [7-9].
According to evidence-based guidelines [10-15], the
most common recommended treatment options for
ADHD include pharmacological and psychological inter-
ventions. Stimulant medication is generally recom-
mended as first-line therapy for school-age children and
adolescents with severe ADHD, along with implementa-
tion of behavioural interventions also recommended
[10-15]. In many Western countries, medications currently
used for the treatment of ADHD include stimulants
(e.g. methylphenidate and amfetamines), non-stimulants
(e.g. atomoxetine, clonidine and guanfacine) and some-
times antidepressants. During the past decade, diag-
nosis rates for ADHD [16,17], medication prescription
[11,18-20] and use of complementary and alternative
medical therapies by young people [21,22] have risen
substantially. However, controversies and public debate
over the appropriate diagnosis and treatment of ADHD
continue to exist [23-28].
Despite the extensive body of research into the epi-
demiology, pathophysiology and treatment of ADHD
[2,3,5,29], less emphasis has been placed on methodo-
logically sound comparative research questions evaluat-
ing and comparing different ADHD treatment options
[24]. For example, which ADHD treatment modality
works best in children and adolescents, psychological or
pharmacological interventions? Among broad groups
of treatment interventions, is there any particular
medication or psychotherapy which is clinically superior
(or inferior) to others? Is there a unique role of comple-
mentary and alternative medicine used in the treatment
of children and adolescents with ADHD? Which treat-
ment comparisons of ADHD interventions is there suffi-
cient data and for which comparisons are more trials
required?
Given the clinical and scientific relevance of these
questions, several important systematic reviews have
been published in the literature. Some of these reviews
are outdated [30-32]. Some reviews were focused on oneparticular treatment approach only [33-40], most often
medications; while others compared medications and
psychological interventions [41,42] for ADHD without
synthesizing all outcome measures of clinical import-
ance. To our knowledge, none of these previous reviews
attempted to establish evidence-based hierarchies for the
efficacy and safety of all pharmacological and non-
pharmacological treatments in a comprehensive review
using network meta-analysis. Network meta-analysis is a
relatively new evidence synthesis approach which allows
the synthesis of data from both direct (head-to-head,
when treatments are compared within a randomized
trial) and indirect comparisons (when treatments are
compared between trials by combining results using a
common comparator) [43,44].
The aim of this systematic review is to address the fol-
lowing research question: For children and adolescents
with ADHD, what is the comparative efficacy and safety
of competing pharmacological and non-pharmacological
treatments?
Methods
The proposed systematic review will be conducted in ac-
cordance with the reporting guidance provided in the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement (http://www.prisma-
statement.org/).
This systematic review and network meta-analysis
protocol is registered in the PROSPERO database
(CRD42014015008.).
Study eligibility criteria
Type of studies
Only randomized controlled trials (RCTs) of a minimum
of a 3-week duration will be included in this review
(3 weeks per treatment arm in parallel-group studies
and 3 weeks in the first randomisation period for cross-
over studies). This duration has been chosen because
existing research suggests that 3 to 4 weeks on stable
medication is the minimum length of treatment chosen
in trials designed to measure dose responses [45] or
treatment efficacy [32] in subjects with ADHD.
RCTs comparing one pharmacological treatment or
non-pharmacological treatments (as monotherapy or in
combination) against another or against placebo/control
in the treatment of children and adolescents with ADHD
will be included.
For trials which have a crossover design, only data
from the first randomisation period will be considered
due to concerns over carryover effects [46].
Studies of both first-line treatment (defined as the first
intervention given to patients) and second-line treat-
ment (defined as the second intervention administered
either as a result of failure of or suboptimal response to
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in studies reporting results of at least one of the out-
comes of interest as well as the number of ADHD pa-
tients enrolled in each treatment arm and the number of
ADHD patients with events in each treatment arm.
Type of participants
Studies that enrolled children and adolescents (under
18 years of age) with a clinical diagnosis of ADHD as
per either the Diagnostic and Statistical Manual of Men-
tal Disorders (e.g. DSM-IV criteria) or the International
Classification of Diseases (e.g. ICD-10 hyperkinetic dis-
orders) criteria will be sought. All ADHD subtypes (e.g.
combined type, predominantly inattentive and predom-
inantly hyperactive/impulsive) will be considered for
inclusion.
Studies including patients with comorbid conditions
(such as anxiety, depression, epilepsy or other medical
conditions) will also be eligible for inclusion.
Type of interventions
We will consider studies evaluating the following
treatments:
Pharmacological interventions
Pharmacological interventions refer to the treatment of
ADHD using medication, under the supervision of a
medical professional. Studies evaluating any of the fol-
lowing drugs at any therapeutic dose will be considered:
 Stimulant drugs: methylphenidate,
dexmethylphenidate, dexamfetamine/
dextroamfetamine, mixed amphetamine salts,
lisdexamfetamine.
 Non-stimulant drugs: atomoxetine, guanfacine,
clonidine.
 Other approved or unapproved drugs used in
ADHD: stimulants (modafinil) and antidepressants
(bupropion, venlafaxine, reboxetine, desipramine,
imipramine, nortriptyline, clomipramine,
amitriptyline).
Psychological interventions
A diverse range of psychological therapies is available for
the treatment of ADHD in children and adolescents.
Based on a previous systematic review [47], psychological
interventions will be categorized into three domains.
 Behavioural interventions: those interventions
directed at changing behaviours (increasing desired
behaviours and decreasing undesired behaviours),
based on social learning principles and other
cognitive theories. These include classical
contingency management, behaviour therapy(mainly through mediators such as parents or
teachers) and cognitive behaviour therapy (such as
verbal self instruction, problem solving strategies
or social skills training [47]). These treatments
are usually offered in several sessions over time,
either through training the mediator(s) or the
child or both.
 Cognitive training: working memory training
incorporating adaptive schedules that are hypothesized
to strengthen ADHD-deficient neuropsychological
processes. As in Sonuga-Barke et al. (2013) [47], we
will only retain studies including training interventions
that aim to directly train a cognitive function, or
working memory, or attention.
 Neurofeedback using the visualization of brain
activity to teach children to increase attention
and impulse control. Neurofeedback is commonly
based on electroencephalography; sensors are
placed on the scalp to measure activity, and
measurements displayed using video displays or
sound. By learning to control their brain activity
based on behavioural principles of operant
conditioning, it is hypothesized that ADHD
patients will learn to regulate the associated
attentional states and processes [47].
A priori, the duration of the psychological interven-
tions will have to be between time frames of ADHD
drug therapy (e.g. at least 3 to 12 weeks for initial short-
term phase of treatment, at least 24 weeks for mid-term
treatment and more than 48 weeks for long-term
treatment).
Complementary and alternative medicine
Complementary and alternative medicine (CAM), as
defined by the National Center for Complementary
and Alternative Medicine (NCCAM) - U.S. National
Institutes of Health (http://nccam.nih.gov/), is a group of
diverse medical and health care systems, practices and
products that are not presently considered to be part of
conventional medicine. Complementary medicine in-
cludes treatments that are used together with conven-
tional medicine, whereas alternative medicine treatments
are used in place of conventional medicine. A diverse
range of CAM interventions are being used for the treat-
ment of ADHD in children and adolescents. Based on
NCCAM and expert [48,49] taxonomy, we will categorize
CAM into three different types:
 Dietary interventions, such as:
i. Restricted elimination diet or ‘few foods
approach’ (exclusion of items associated with
food hypersensitivity, sometimes referred to as
an oligoantigenic diet).
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(e.g. removing food colours such as azo dyes,
tartrazine, carmoisine, sunset yellow, brilliant
blue, indigotine, allura red, quinoline yellow or
ponceau 4R).
iii. Any other food related interventions. Supplementary interventions:
i. Polyunsaturated fatty acids (PUFA e.g. omega-3
and omega-6 fatty acids).
ii. Vitamins (e.g. vitamin B6, vitamin B9, vitamin
B12, vitamin C, multiple vitamins).
iii. Minerals (e.g. magnesium, zinc, iron, calcium).
iv. Aminoacids (e.g. acetyl-L-carnitine, gamma-
aminobutyric acid, glycine, L-tyrosine).
v. Herbal treatment (e.g. Ginkgo Biloba, Ginseng, St
John’s Wort/Hypericum perforatum, Valerian).
vi. Homeopathic treatment.
vii.Any other supplementary interventions. Mind- and body-based interventions:
i. Massage, chiropractic and osteopathic manipulation,
acupuncture, yoga, meditation, Tai chi, etc.Control comparators. Eligible control conditions will
be placebo (psychological or pill), waitlist (in psycho-
logical studies), no treatment or usual care. These may
act as vital links for the incorporation of indirect evi-
dence in the treatment networks, and are thus important
to include (see data synthesis subsection).
Types of outcome measures
The pre-specified primary endpoints will be pragmatic
outcomes such as the proportion of patients who
responded to or dropped out of the allocated treatment.
 Treatment efficacy (as a dichotomous outcome). We
will use response rate as a dichotomous outcome
instead of a continuous ADHD symptom score to
make the interpretation of results easier for clinicians,
patients, parents, teachers, caregivers and decision
makers. We will use the number of patients who
respond to treatment, based on improvements on
standardized rating scales used in clinical trials such as
the overall ADHD Rating Scale (ADHD-RS) [50], the
Clinical Global Impression-Improvement scale (GGI-I)
[50], the Clinical Global Impressions-Severity scale
(CGI-S) [51], the Swanson, Nolan and Pelham (SNAP)
Rating Scale [52], the Conner’s Rating Scale [53]
or any other validated rating scale, at the end of
treatment. Many studies define response to therapy as
25% to 30% or greater improvement in core symptoms
(e.g. ADHD-RS ≥25% to 30%), a global rating of
‘much’ or ‘very much’ improved (e.g. CGI-I ≤2) or‘no symptoms’ or ‘minimal symptoms’ (e.g. CGI-S ≤2)
[54]. In this review, any definition of response to
therapy and any version of validated scales with
pre-defined cut-off points for this specific age group
will be accepted. We will capture the response criteria
used in each trial and data will be extracted in order to
explore potential impact on treatment effects if there
are different cut-off points used for the same scale,
or exclusion of those studies not using established
cut-off values (e.g. other than ADHD-RS ≥25% to
30% or CGI-I ≤2). If the original authors report
several outcomes corresponding with our definition
of treatment response, we will give preferences to the
following scales in this order: 1) CGI, 2) ADHD-RS,
3) SNAP, 4) Conner’s and 5) other. This approach
was based on expert opinions from our review team.
We will also give preference to measures rated by
clinicians (followed by teachers/parents and patients).
Responders to treatment will be calculated on an
intention-to treat basis based on the total number of
randomly assigned participants, irrespective of how
original study investigators reported data. We will
contact authors for missing outcome data or unclear
information (e.g. up to three times). Where the
number of responders to treatment is unreported
and contact with authors fails to acquire this data,
we will use an approach applied in recent research
[55] to impute outcomes for the missing participants
assuming that they did not respond to treatment.
When dichotomous outcomes are not reported in
studies, but baseline scores, endpoint means and
standard deviations (SD) of the rating scales are
provided, we will attempt to estimate the number
of patients responding to treatment with the validated
imputation method previously employed by Furukawa
et al. (2005) [56].
 All-cause treatment discontinuation (as a
dichotomous outcome), defined as the proportion of
patients who leave the study early for any reason as
defined by the authors at the longest available
follow-up, will also be collected.
Secondary outcomes will include the following:
 Tolerability of treatment (as a dichotomous
outcome) measured by the proportion of patients
who have left the study early due to adverse events
as defined by the authors at the longest available
follow-up.
 Serious adverse events (as a dichotomous outcome)
defined as the occurrence of any untoward medical
event that results in death, is life-threatening, requires
inpatient hospitalization or prolongs existing
hospitalization, results in persistent or significant
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birth defect, or is an Important Medical Event.
Important Medical Events are events that may have
been considered as serious adverse events when,
based upon medical judgement, they may jeopardize
the patient and may require medical or surgical
intervention to prevent one of the outcomes
listed above.
 Specific adverse events (as dichotomous outcomes)
including the occurrence of decreased appetite,
decreased weight, anorexia, insomnia and sleep
disturbances, anxiety, syncope, any cardiovascular
effect (e.g. hypertension, alterations in heart rate).
Study-specific definitions of these events will be
recorded to account for variations in definition.
Because of the chronic course of ADHD, we will dif-
ferentiate outcomes measured during initial short-term
treatment (e.g. the first 6 weeks of treatment with a
range 3 to 12 weeks), mid-term treatment (e.g. 24 weeks
of treatment with a range 13 to 48 weeks) and long-term
treatment (e.g. more than 48 weeks). This arbitrary dis-
tinction does not imply that more than 24 weeks of
treatment defines optimal length of treatment but fol-
lows current recommendations on the clinical investiga-
tion of pharmacological treatments for ADHD [45].
Search methods for identification of studies
Based on our awareness of a large number of existing re-
views and meta-analyses that can be utilized, an unlim-
ited primary search for RCTs will not be conducted. In
its place, we will use a staged approach to study identifi-
cation, beginning with the identification of relevant ran-
domized trials included in systematic reviews searched
for in PubMed/MEDLINE and the Cochrane Database
of Systematic Reviews (publication years 2005 and
onward), existing systematic reviews, meta-analyses
and health technology assessment (HTA) reports which
we are aware of [30-42,57-62]. A draft search strategy is
included in the Appendix. From identified systematic
reviews, we will screen reference lists of both included
and excluded studies.
Next, we will search PubMed/MEDLINE to identify
other additional relevant RCTs published outside the
time frames of these reviews. We will compile a list of
the unique PubMed/MEDLINE identification numbers
of all relevant articles from the systematic review search
and perform a related articles search. This technique has
been shown to be effective in identifying relevant stud-
ies, has been used recently by reviews in several clinical
fields and increases efficiency in study identification in
the presence of an already large evidence base [63,64].
These searches will be supplemented by searches in
alternative databases (PsycINFO, CINAHL and AMED[65]), and by scrutiny of clinical trial registers (including
www.clinicaltrials.gov), HTA agencies (e.g. the National
Institute for Health and Care Excellence in the UK, the
U.S. Agency for Healthcare Research and Quality and
the Canadian Agency for Drugs and Technologies in
Health), regulatory bodies (e.g. the U.S. Foods and Drug
Administration and the European Medicines Agency)
and review of references of relevant papers and clinical
practice guidelines.
We will also contact authors of primary publications,
collaborators and/or sponsors of clinical trials to check
if they are aware of any trials we may have missed.
Data collection and risk of bias assessment
Eligible RCTs identified from our searching efforts will
be screened by two researchers and will be verified by a
third researcher of the team to confirm whether each
study meets our eligibility criteria. Using a pre-designed
form that will be piloted initially on a small number of
included studies, the same reviewers will be also respon-
sible for extraction and verification of data on general
characteristics (e.g. average age, gender distribution, dur-
ation of ADHD, initial severity of ADHD, patient comor-
bidity history, past/present medication use, mean or
median follow-up), characteristics related interventions
(such as drug dose or therapist competence in the case
of psychotherapy interventions, e.g. therapist qualifica-
tion, years of experience), outcomes and study design
from included studies. If outcomes are not reported at
the predefined time points, we will extract data as close
as possible to that time point.
The Cochrane Risk of Bias tool [66], which considers
sequence generation, allocation concealment, and blind-
ing and other aspects of bias will be used to assess the
study risk of bias. The overall rating of risk of bias for
each study will be the lowest rating for any of the cri-
teria (e.g. if any domain is scored high risk of bias, the
study will be considered high risk of bias). Any discrep-
ancies between reviewers for any of the above steps
will be discussed by the reviewers until consensus is
achieved.
We will also contact authors of primary publications,
collaborators and/or sponsors of clinical trials for miss-
ing outcome data or unclear information.
Data synthesis
We will begin with a narrative overview of studies in-
cluded in the review which will provide insights regard-
ing descriptive characteristics of the study populations
(e.g. age, gender, ADHD subtype, comorbidities, severity
of illness) and trial characteristics, describing the types
of comparisons made as well as other important vari-
ables (such as year of publication, geographic region and
sponsorship in case of drug trials). We will use GRADE
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for outcomes (e.g. high quality, moderate quality and
low quality).
Standard pairwise meta-analysis
We will perform standard pairwise meta-analyses using
a random effects model when data are available. We will
evaluate heterogeneity by estimating the variance be-
tween studies (chi-square test [68] and I2 statistic [69]).
We will report the results as odds ratios (ORs) and cor-
responding 95% confidence intervals (CIs). Studies of
first-line treatment (defined as the first intervention
given to patients) and second-line treatment (defined
as the second intervention administered either as a
result of failure of or suboptimal response to first-line
treatment) will be analysed separately due to the hetero-
geneity of the intervention.
Network geometry
We will describe and present graphically the geometry
of the treatment network of comparisons across studies
to determine if a network meta-analysis is feasible; we
will also identify parts of the treatment networks with
considerable evidence versus little or no evidence [70].
The geometry of the treatment network (or network
geometry) addresses what the shape of the treatment
comparisons looks like in terms of the number of in-
cluded interventions (e.g. treatment nodes), the ex-
tent to which there are trials comparing different
pairs of these interventions (e.g. the adjoining lines
or ‘edges’) and the numbers of patients associated
with different comparisons. By studying and present-
ing the network geometry, one can develop an un-
derstanding of how strong the evidence is for some
treatment comparisons and whether specific compari-
sons are selected, under-represented or even avoided
in identified studies [70,71].
Depending on the pattern of studies included, we will
explore whether sensitivity analyses related to network
geometry are feasible using different classifications to
see how stable our results are. We will consider issues
including the consideration of treatment nodes for dif-
ferent drug dosages or conducting analyses including all
behavioural interventions as a class versus independent
analyses (e.g. parent training only, parent/child training
or parent/child/teacher training). Control comparators
will initially be treated as separate nodes in the networks
and combined if effect sizes are relatively similar for
them.
Network meta-analysis
If the assumptions of homogeneity and similarity are
judged reasonable based on review of study characteris-
tics within and across connections in the network ofinterventions, network meta-analysis will be carried out
for each clinical outcome separately. Network meta-
analysis is a statistical method used to synthesize infor-
mation from a network of trials addressing the same
question but involving multiple treatments, as well as
situations involving the availability of both direct and
indirect data for comparisons of interest [43,44,71,72].
Network meta-analyses have been applied in many fields
of medicine and clinical psychiatry [55,73,74] to evaluate
jointly the comparative safety and effectiveness of mul-
tiple available interventions for a condition of interest,
even when some of them have not been directly com-
pared in primary research studies. This evidence synthe-
sis method uses both direct (head-to-head) and indirect
evidence from all RCTs to be combined into a single
effect size for each pairwise comparison and can also be
used to estimate comparisons between pairs of treat-
ments which have not been compared in individual stud-
ies. By including the combination of direct and indirect
evidence, a network meta-analysis may increase preci-
sion in estimates and facilitate simultaneous compari-
sons while within-trial randomization is preserved [43].
In our review, network meta-analyses will be per-
formed within a Bayesian framework using WinBUGS
1.4.3 (MRC Biostatistics Unit, Cambridge, UK) with
random effects models adjusting for correlation of
multi-arm trials [72] using vague prior distributions
throughout. We will report the results as median ORs
and corresponding 95% credibility intervals (CrIs), which
are the Bayesian analogue of 95% CIs. In addition to es-
timating ORs, we will also estimate median treatment
ranks with 95% CrIs as well as the Surface Under the
Cumulative RAnking curve (SUCRA) values [75]. SUCRA
values are expressed as percentages; if a treatment is cer-
tainly the best, its SUCRA value would be 100%, and if a
treatment is certainly the worst, its SUCRA value would be
0%. Forest plots of summary effect sizes as well as ranko-
grams [75] will be used to present main findings.
We will assess model convergence on the basis of in-
spection of Brooks-Gelman-Rubin plots [76] and Monte
Carlo errors.
Exploring sources of heterogeneity
Findings from risk of bias assessments of included stud-
ies will be used to inform sensitivity analyses including
meta-regression [77] or exclusion of higher risk of bias
studies and/or small studies to address the impact of
perceived study deficiencies. Meta-regression and/or re-
moval of studies from the treatment network to address
clinically important variations between studies such as
mean age, gender, ADHD severity, presence of comor-
bidities and year of publication (as a proxy measure of
potential changes in clinical practice over time) will also
be explored.
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analyses by age-group (e.g. children: <12 years old vs
adolescents: 12 to 17 years old).
We will also conduct sensitivity analyses according to
the following variables: study design (e.g. including only
studies where both the assessor and the patient were
blind, sometimes referred as ‘double-blind’ trials), imput-
ation (including only studies without imputation of
response rates), response rate definition (e.g. using the
most common definition in the included studies) and
rating informant (e.g. including only clinician ratings).
Assessment of inconsistency
When performing a network meta-analysis, we rely on
the assumption of consistency (equivalency of treatment
effects from direct and indirect evidence) across the dif-
ferent comparisons in the network. The consistency of
results will be examined by comparing the results ob-
tained via pairwise meta-analysis versus network meta-
analysis. This will also be examined by fitting both
consistency and inconsistency models for network meta-
analysis and comparing the deviance information criteria
(DIC) between models [78], with smaller values indica-
tive of better fit and a difference of 5 or more being con-
sidered as important. If both models have a similar fit to
the data as indicated by their DIC values, we will
conclude there does not appear to be evidence of incon-
sistency. Scatterplots of the residuals from both models
will also be examined.
Discussion
This systematic review will evaluate the comparative
efficacy and safety of pharmacological and non-
pharmacological interventions used in children and
adolescents with ADHD. In addition, this review
could provide hierarchical information of the multiple
competing interventions for ADHD in terms of compara-
tive efficacy (response rates) and safety (all-treatment dis-
continuations, discontinuations due to adverse events,
serious adverse events and selected adverse events). This
will produce clinically relevant information that may
facilitate understanding the benefit-risk profiles of
pharmacological interventions, psychological treatments
and CAM in ADHD.
There are several strengths and limitations of our
planned methods. In terms of strengths, we will compre-
hensively review a significant amount of data from both
published and unpublished evidence from a range of
sources (e.g. journal articles, clinical study reports,
trialists/sponsors communications). Also, we have se-
lected for our primary efficacy outcome of response
rate to use a dichotomous rather than continuous measure
(e.g. standardized mean difference), because from a clinical
perspective, syntheses of continuous outcomes measuredon different scales can be difficult to interpret [56,79].
However, a limitation of this method is that there can
be a substantial information loss when continuous out-
come variables are dichotomized [80]. Another limita-
tion is that based on knowledge from previous reviews,
we anticipate identifying studies using different study
designs, diverse durations, small sample sizes and dif-
ferent end-point definitions, which may increase statis-
tical heterogeneity. Further, the possibility of selective
outcome reporting bias (mainly, for unpublished data
on harms) in ADHD trials could be a potential limita-
tion of this review.
We hope that our findings will assist patients, clinicians
and healthcare providers to make evidence-based decisions
regarding treatment selection. Our findings could also
potentially be useful for informing the development of
evidence-based guidelines as well as the future design of a
research agenda of new randomized trials in the field.
Appendix
Appendix: Key terms for PubMed/MEDLINE search.
Medical condition terms:
#1. “(attention deficit disorder with hyperactivity OR
adhd OR hyperkinetic* OR inattent* OR impulsivity OR
hyperkinesis OR tdah)”
Population group terms:
#2. “(child OR children OR adolescent* OR pediatric*
OR paediatric*)”
Systematic review/meta-analysis terms:
#3. “(meta-analy* OR metanaly* OR metaanaly* OR
met analy* OR integrative research OR research integra-
tion OR research overview* OR collaborative review*
OR systematic review* OR systematic overview* OR
evidence-based review* OR evidence-based OR overview*
OR meta-review* OR review of reviews OR technology
assessment* OR HTA)”
Interventions terms:
#4. “(methylphenidate OR equasym OR ritalin OR
concerta OR rubifen OR tranquilyn OR phenidylate OR
methyl phenidate OR dexmethylphenidate OR focalin
OR metilfenidato OR dextroamphetamine OR dexam-
phetamine OR dexamfetamine OR elvanse OR vyvanse
OR venvanse OR tyvense OR d amphetamine OR am-
phetamine OR Adderall OR dexedrine OR lisdexamfeta-
mine OR atomoxetine OR tomoxetine OR strattera OR
guanfacine OR guanfacina OR tenex OR intuniv OR
clonidine OR kapvay OR nexiclon OR catapres OR mod-
afinil OR bupropion OR venlafaxine OR reboxetine OR
desipramine OR imipramine OR nortriptyline OR clo-
mipramine OR amitriptyline OR antidepressant* OR
contingency management OR management techniques
OR contingency techniques OR psychosocial interven-
tions OR psychosocial treatment OR psychosocial ther-
apy OR social skills training OR social skills intervention
Catalá-López et al. Systematic Reviews  (2015) 4:19 Page 8 of 10OR social skills treatment OR problem solving interven-
tion OR problem solving treatment OR problem solving
training OR problem solving therapy OR behavior modi-
fication OR cognitive behavior treatment OR cognitive
behavior therapy OR cognitive behavior training OR par-
ent training OR parent counselling OR parent support
OR school-based OR classroombased OR school inter-
vention OR classroom intervention OR teacher training
OR after-school or remedial teaching OR peer tutoring
OR computer assistance learning OR task modifica-
tion OR curriculum modification OR classroom man-
agement OR education intervention OR multimodal
intervention OR multimodal treatment OR multimodal
therapy OR multimodal intervention OR multimodal
treatment OR multimodal therapy OR educational inter-
vention OR and verbal self-instruction training OR
cognitive training OR attention training OR working
memory training OR cognitive remediation OR executive
function training OR and cognitive control OR neuro-
feedback OR EEG biofeedback OR neurotherapy OR
slow cortical potentials OR few foods diet OR elimination
diet OR oligoantigenic diet OR restriction diet OR food
intolerance OR food allergy OR and food hypersensitivity
OR food color OR food dye OR Feingold diet OR Kaiser
Permanente diet OR K-P diet OR tartrazine OR azo dye
OR carmoisine OR sunset yellow OR brilliant blue OR
indigotine OR allura red OR quinoline yellow OR pon-
ceau 4R OR essential fatty acid OR long-chain polyunsat-
urated fatty acids OR PUFA OR omega-3 OR omega-6
OR docosahexaenoic acid OR eicosapentaenoic acid OR
arachidonic acid OR vitamin B6 OR pyridoxine OR vita-
min B9 OR folate OR vitamin B12 OR cobalamin OR
magnesium OR zinc OR iron OR calcium OR ami-
noacid OR amino acid OR carnitine OR L-carnitine
OR L-tyrosine OR tyrosine OR tryptophan OR glycine OR
melatonin OR taurine OR 5-HTP OR phenilalananine
OR aspartame OR ginkgo OR ginkgo biloba OR ginseng
OR St John’s Wort OR hypericum perforatum OR rho-
diola OR chamomile OR valerian OR bacopa OR pinus
marinus OR massage OR chiropractic OR osteopathic ma-
nipulation OR acupuncture OR yoga OR meditation OR
Tai chi OR complementary medicine OR alternative medi-
cine OR complementary and alternative medicine)”
Combination of terms:
#5. #1 AND #2 AND #3 AND #4Abbreviations
ADHD: attention deficit hyperactivity disorders; ADHD-RS: ADHD Rating Scale;
CAM: complementary and alternative medicine; CGI-I: Clinical Global
Impression-Improvement scale; CGI-S: Clinical Global Impressions-Severity
scale; DALYs: disability-adjusted life years; DIC: deviance information criteria;
DSM: Diagnostic and Statistical Manual of Mental Disorders; HTA: health
technology assessment; ICD: International Classification of Diseases;
NCCAM: National Center for Complementary and Alternative Medicine;
RCTs: randomized controlled trials; SNAP: Swanson, Nolan and Pelham rating
scale; SUCRA: Surface Under the Cumulative RAnking curve.Competing interests
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